T-1301 Phase I clinical trial was initiated in Mid-December, 2021 in multiple centers in Taiwan. Getting through the tough 2022Q2 due to COVID-19 affected patient recruitment, the enrollment of the first patient (First-patient-in, FPI) was accomplished in August, 2022. Meanwhile, patient recruitment is ongoing. T-1301 is a small molecular multi-target tyrosine kinase inhibitor (TKI), exhibiting potential of multiple anti-cancer indications. …

The discovery and development of our first-in-class Hec1/Nek2 inhibitor, oral anti-cancer drug T-1101 (Tosylate), have been accepted for an oral presentation at the 19th Annual Congress of International Drug DiscoveryScience & Technology (IDDST-2023).

T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021 in multiple centers in Taiwan. T-1301 is a small molecular multi-target tyrosine kinase inhibitor (TKI), exhibiting potential of multiple anti-cancer indications. The Phase I trial is to evaluate safety and tolerability of T-1301, the recommended Phase 2 dose (RP2D), and the pharmacokinetics in human, and to assess the …

National Health Research Institutes (NHRI) and Taivex Therapeutics Corp (Taivex) have signed the technology transfer agreement in September, 2021. Taivex has granted the exclusive rights of the small molecule Mertansine conjugate, T-1501, with global patents. About DBPR186Phospholipid phosphatidylserine (PS), abundant on the external surfaces of cancer cells, is an established target molecule for cancer therapy. T-1501 is a developmental drug candidate for …